Adherium (ASX: ADR) turns pilot into performance with RPM success across Allergy Partners

Adherium Limited (ASX: ADR), the Melbourne-based digital health company known for its Hailie Smartinhaler platform, has reached a major milestone in its U.S. expansion strategy through its partnership with Allergy Partners. Despite trading at a low of AUD 0.004 and posting a 53 percent decline over the past 12 months, the company is now showing early signs of commercial traction that investors have long waited for.

As of November 2025, Adherium has successfully integrated its Remote Patient Monitoring (RPM) platform across more than 70 percent of Allergy Partners’ 110-plus clinics in the United States. With nearly 700 patients already onboarded and actively monitored, the partnership is no longer in pilot phase. It has become a scaled, revenue-generating operation. This integration allows clinics to bill insurers using U.S. Medicare and private payer RPM and Remote Therapeutic Monitoring (RTM) codes, marking a transition from proof-of-concept to proof-of-revenue.

The rollout aims to reach approximately 4,000 active patients by the end of calendar year 2025, creating a recurring fee-for-service revenue stream built on digital respiratory monitoring. For a company that has historically struggled to monetise its connected health technology, this transition could alter its trajectory heading into 2026.

How the RPM billing model is powering Adherium’s transition to a recurring revenue business

At the heart of this momentum is Adherium’s Hailie Smartinhaler platform, a U.S. Food and Drug Administration-cleared sensor-based system designed to help asthma and chronic obstructive pulmonary disease (COPD) patients track and improve medication adherence. With Allergy Partners clinicians now integrating Hailie into their workflows, the clinical deployment directly supports insurance reimbursements through RPM billing codes.

Adherium is now responsible for end-to-end onboarding of patients, turning each participating clinic into a predictable revenue source. The company’s fee-for-service model aligns with U.S. healthcare reimbursement structures, and as more patients are activated, each unit represents monetisable value. With more than 90,000 asthma patients eligible across the Allergy Partners network, the upside potential is considerable.

The transformation from one-off sensor sales to a repeatable service model addresses a longstanding gap in Adherium’s business. The company had shipped over 180,000 connected devices globally, but lacked a sustainable revenue mechanism until it began anchoring its digital tools within real-time billing ecosystems. Through this collaboration, the linkage between clinical value and cash flow is now fully in motion.

What analysts and investors are watching as Adherium chases 4,000-patient onboarding goal

Adherium’s share price remains stagnant despite this progress. At AUD 0.004 per share, the company sits at the lowest end of its 52-week trading range. The market capitalisation hovers around AUD 10 million, and liquidity is nearly nonexistent, with zero shares traded in the most recent session. Earnings per share remain negative at AUD 0.017 and there is no dividend yield. The healthcare firm ranks 184th out of 236 in its ASX sector and is positioned 1,924th across the broader exchange.

Yet analysts covering early-stage digital health firms view the Allergy Partners collaboration as a proof-of-execution moment. Unlike limited-scope pilots, this partnership now covers 70 percent of one of America’s largest asthma and allergy networks. The agreement has transitioned into a fully managed collaboration, with Adherium handling onboarding, technical implementation, and patient monitoring, all of which are reimbursable activities under U.S. billing standards.

If Adherium meets its year-end target of 4,000 active patients, that growth could validate the model’s scalability and operational efficiency. However, the market remains cautious until those onboarding numbers materially convert into quarter-over-quarter revenue growth and broader network expansion beyond this initial partner.

How clinical leaders are evaluating the impact of Hailie Smartinhaler in chronic respiratory care

Feedback from Allergy Partners leadership has been pivotal in lending credibility to Adherium’s RPM rollout. William A. McCann, MD, Chief Executive Officer of Allergy Partners, stated that the collaboration has provided clinicians with vital insights to proactively manage patients. He highlighted that adherence to controller medication had long been a barrier in asthma care and described Hailie as a game-changing tool that enables clinicians to intervene earlier and reduce the risk of attacks.

For patients, the experience is being supported through digital engagement and education. Allergy Partners has launched a new Hailie resource page on its website, featuring patient testimonials, onboarding instructions, and direct links for exploring the platform. This initiative improves patient awareness, promotes continuous use, and ultimately supports clinic reimbursements by keeping patients engaged in the RPM program.

Adherium’s Chief Executive Officer Dawn Bitz described the rollout as a shift from vision to reality. She noted that having three-quarters of one of the largest U.S. specialty networks fully activated on the platform proves that Adherium has moved beyond theoretical scalability. According to Bitz, monthly patient adoption is now steadily rising, and the operational traction reflects the kind of execution institutional investors had been waiting for.

Why commercial success may not yet be enough to unlock stock upside for Adherium in the near term

Despite the clinical endorsements and operational rollout, the market has not yet priced in Adherium’s progress. The stock remains near all-time lows and investor interest is tepid. The company’s fundamentals remain under pressure, with a negative book value per share of AUD -0.002 and no current earnings or profit guidance. Volume remains weak, and institutional activity is nearly absent.

The risk factors are not insignificant. To achieve meaningful revenue acceleration, Adherium must retain patients within the RPM workflow, avoid high churn, and ensure seamless billing execution at scale. Additionally, expanding the platform into broader U.S. healthcare networks or payer partnerships would require regulatory, operational, and sales infrastructure that may stretch its current resources.

Moreover, with 2.49 billion shares on issue and limited liquidity, even significant operational progress may not easily translate into stock price movement without broader financial re-rating or strategic capital deployment. A new partnership or revenue milestone announcement may be required to re-engage institutional attention.

Still, the Allergy Partners milestone gives Adherium a tangible roadmap. If the company can replicate this partnership model with additional providers or link it to larger hospital networks, the stock could begin a fundamental revaluation. For now, the focus remains on execution, patient growth, and revenue conversion through 2026.

What are the key takeaways from Adherium’s RPM rollout with Allergy Partners?

• Adherium Limited has deployed its Hailie Smartinhaler platform across over 70 percent of Allergy Partners’ 110-plus clinics in the United States.

• Nearly 700 patients have been enrolled in the Remote Patient Monitoring (RPM) program within six months, with a stated target of reaching 4,000 active patients by the end of calendar year 2025.

• The rollout marks a shift from pilot programs to a recurring fee-for-service revenue model supported by U.S. Medicare and private insurance billing codes for RPM and Remote Therapeutic Monitoring (RTM).

• Adherium now manages the full patient onboarding process, turning Allergy Partners into a scalable and monetisable partner in the digital respiratory care space.

• The company’s stock remains flat at AUD 0.004 with low liquidity, negative earnings per share, and weak institutional sentiment despite operational progress.

• Clinical leaders at Allergy Partners have endorsed the platform’s ability to improve medication adherence and proactive care for asthma and COPD patients.

• Investors remain cautious, with the stock ranking 184th in its healthcare sector on the ASX and concerns lingering over scalability, churn, and financial fundamentals.

• Analysts believe the partnership provides a credible roadmap for future U.S. commercial expansion and a potential turning point in Adherium’s financial trajectory if revenue growth continues into 2026.